BAUSCH HEALTH COS INC (BHC.CA) Stock Fundamental Analysis
Canada - TSX:BHC - CA0717341071 - Common Stock
8.96 CAD
-0.05 (-0.55%)
BHC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BHC had positive earnings in the past year.
In the past year BHC had a positive cash flow from operations.
In the past 5 years BHC always reported negative net income.
Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
BHC has a Return On Assets of 0.36%. This is in the better half of the industry: BHC outperforms 73.53% of its industry peers.
BHC has a better Return On Invested Capital (6.09%) than 88.24% of its industry peers.
BHC had an Average Return On Invested Capital over the past 3 years of 5.45%. This is below the industry average of 8.10%.
The last Return On Invested Capital (6.09%) for BHC is above the 3 year average (5.45%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.36% | ||
| ROE | N/A | ||
| ROIC | 6.09% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
1.3 Margins
BHC has a better Profit Margin (0.99%) than 76.47% of its industry peers.
BHC's Operating Margin of 19.13% is amongst the best of the industry. BHC outperforms 88.24% of its industry peers.
BHC's Operating Margin has improved in the last couple of years.
The Gross Margin of BHC (70.70%) is better than 91.18% of its industry peers.
BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.13% | ||
| PM (TTM) | 0.99% | ||
| GM | 70.7% |
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BHC is destroying value.
Compared to 1 year ago, BHC has more shares outstanding
Compared to 5 years ago, BHC has more shares outstanding
The debt/assets ratio for BHC has been reduced compared to a year ago.
2.2 Solvency
BHC has an Altman-Z score of 0.21. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
BHC's Altman-Z score of 0.21 is fine compared to the rest of the industry. BHC outperforms 64.71% of its industry peers.
BHC has a debt to FCF ratio of 19.69. This is a negative value and a sign of low solvency as BHC would need 19.69 years to pay back of all of its debts.
BHC has a Debt to FCF ratio of 19.69. This is in the better half of the industry: BHC outperforms 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.69 | ||
| Altman-Z | 0.21 |
ROIC/WACC0.91
WACC6.73%
2.3 Liquidity
BHC has a Current Ratio of 1.31. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
BHC has a Current ratio of 1.31. This is in the lower half of the industry: BHC underperforms 67.65% of its industry peers.
A Quick Ratio of 0.98 indicates that BHC may have some problems paying its short term obligations.
BHC's Quick ratio of 0.98 is on the low side compared to the rest of the industry. BHC is outperformed by 61.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.55% over the past year.
BHC shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.91% yearly.
The Revenue has been growing slightly by 7.13% in the past year.
BHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.28% yearly.
EPS 1Y (TTM)3.55%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.25%
Revenue 1Y (TTM)7.13%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%5.29%
3.2 Future
Based on estimates for the next years, BHC will show a decrease in Earnings Per Share. The EPS will decrease by -0.15% on average per year.
BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.19% yearly.
EPS Next Y5.02%
EPS Next 2Y7.99%
EPS Next 3Y11.04%
EPS Next 5Y-0.15%
Revenue Next Year5.61%
Revenue Next 2Y4.68%
Revenue Next 3Y3.21%
Revenue Next 5Y-0.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 1.70 indicates a rather cheap valuation of BHC.
Based on the Price/Earnings ratio, BHC is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of BHC to the average of the S&P500 Index (27.76), we can say BHC is valued rather cheaply.
A Price/Forward Earnings ratio of 1.46 indicates a rather cheap valuation of BHC.
Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.18. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.7 | ||
| Fwd PE | 1.46 |
4.2 Price Multiples
BHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BHC is cheaper than 91.18% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.15 | ||
| EV/EBITDA | 7.16 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BHC has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y7.99%
EPS Next 3Y11.04%
5. Dividend
5.1 Amount
No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:BHC (9/30/2025, 7:00:00 PM)
8.96
-0.05 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.96%
Inst Owner ChangeN/A
Ins Owners10.81%
Ins Owner ChangeN/A
Market Cap3.31B
Analysts48.89
Price Target10.2 (13.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.1%
Min EPS beat(2)-25.13%
Max EPS beat(2)-7.07%
EPS beat(4)1
Avg EPS beat(4)-7.65%
Min EPS beat(4)-25.13%
Max EPS beat(4)5.95%
EPS beat(8)4
Avg EPS beat(8)-2.65%
EPS beat(12)6
Avg EPS beat(12)-3.66%
EPS beat(16)8
Avg EPS beat(16)-5.48%
Revenue beat(2)1
Avg Revenue beat(2)-0.61%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)0.36%
Revenue beat(4)3
Avg Revenue beat(4)0.46%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.66%
Revenue beat(8)6
Avg Revenue beat(8)1.15%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)8
Avg Revenue beat(16)-0.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.7 | ||
| Fwd PE | 1.46 | ||
| P/S | 0.24 | ||
| P/FCF | 2.15 | ||
| P/OCF | 1.58 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.16 |
EPS(TTM)5.28
EY58.93%
EPS(NY)6.13
Fwd EY68.37%
FCF(TTM)4.16
FCFY46.42%
OCF(TTM)5.67
OCFY63.33%
SpS37.14
BVpS-2.88
TBVpS-64.46
PEG (NY)0.34
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.36% | ||
| ROE | N/A | ||
| ROCE | 8.46% | ||
| ROIC | 6.09% | ||
| ROICexc | 6.6% | ||
| ROICexgc | 32.19% | ||
| OM | 19.13% | ||
| PM (TTM) | 0.99% | ||
| GM | 70.7% | ||
| FCFM | 11.2% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
ROICexc(3y)5.7%
ROICexc(5y)5.13%
ROICexgc(3y)40.1%
ROICexgc(5y)34.22%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexcg growth 3Y34.27%
ROICexcg growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score7
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.69 | ||
| Debt/EBITDA | 6.67 | ||
| Cap/Depr | 32.39% | ||
| Cap/Sales | 4.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 48.16% | ||
| Profit Quality | 1126.53% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 0.21 |
F-Score7
WACC6.73%
ROIC/WACC0.91
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.55%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.25%
EPS Next Y5.02%
EPS Next 2Y7.99%
EPS Next 3Y11.04%
EPS Next 5Y-0.15%
Revenue 1Y (TTM)7.13%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%5.29%
Revenue Next Year5.61%
Revenue Next 2Y4.68%
Revenue Next 3Y3.21%
Revenue Next 5Y-0.19%
EBIT growth 1Y10.04%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year12.61%
EBIT Next 3Y9.06%
EBIT Next 5Y-0.22%
FCF growth 1Y266.02%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y451.87%
OCF growth 3Y3.85%
OCF growth 5Y1.25%